Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients

Transplantation

Volumn 69, Issue 3, 2000, Pages 376-383

  Schrama, Yvonne C ^a   Joles, Jaap A ^a   Van Tol, Arie ^b   Boer, Peter ^a   Koomans, Hein A ^a   Hené, Ronald J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; VASCULAR RESISTANCE;

EID: 0033994423     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002150-00012     Document Type: Article

References (74)

1. MMF. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 1: 1321.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
3. Anonymous. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029.
4. Raine AE. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10 (Suppl 1): 95.
5. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
6. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321: 287.
7. McNally PG, Feehally J Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations (see comments). Nephrol Dial Transplant 1992; 7: 791.
8. Markell MS, Sumrani N, DiBenedetto A, Friedman EA. Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis 1993; 22: 233.
9. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471.
10. Sanders CE Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995; 52: S43.
11. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
12. Dimeny E, Fellstrom B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant 1997; 12: 21.
13. Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation (see comments). Lancet 1995; 1: 610.
14. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661.
15. Thomson SC, Tucker BJ, Gabbai F, Blantz RC. Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats. J Clin Invest 1989; 83: 960.
16. Abraham JS, Bentley FR, Garrison RN, Cryer HM. Cyclosporine A directly constricts intrarenal arterioles. Transplant Proc 1991; 23: 356.
17. Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56.
18. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706.
19. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767.
20. Sullivan BA, Hak LJ, Finn WF. Cyclosporine nephrotoxicity: studies in laboratory animals. Transplant Proc 1985; 17: 145.
21. Dieperink H, Leyssac PP, Starklint H, Kemp E. Nephrotoxicity of cyclosporin A. A lithium clearance and micropuncture study in rats. Eur J Clin Invest 1986; 16: 69.
22. Versluis DJ, Wenting GJ, Derkx FH, Schalekamp MA, Jeekel J, Weimar W. Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantation 1987; 44: 387.
23. Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation 1991; 52: 64.
24. Hoitsma AJ, Wetzels JF, van Lier HJ, Berden JH, Koene RA. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1987; 1: 584.
25. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499.
26. Kootte AM, Lensen LM, van Bockel JH, van Es LA, Paul LC. High- and low-dose regimens of cyclosporin in renal transplantation: immunosuppressive efficacy and side-effects. Nephrol Dial Transplant 1988; 3: 666.
27. Sutherland F, Burgess E, Klassen J, Buckle S, Paul LC. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transplant Int 1993; 6: 129.
28. Zietse R, van Ierland van Leeuwen ML, Derkx FH, IJzermans JN, Schalekamp MA, Weimar W. Glomerular barrier function following conversion from cyclosporine to azathioprine in renal transplant recipients. Am J Kidney Dis 1994; 24: 927.
29. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 2073.
30. Salas M, Loertscher R, Caro JJ. Effect of cyclosprin weaning on glomerular filtration rate in renal transplantation. Nephron 1996; 74: 309.
31. Dorpel vanden MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304.
32. Shen SY, Weir MR, Coughlin TR. Renal allograft biopsy and conversion of cyclosporine to azathioprine. Transplantation 1989; 47: 223.
33. Helling RB. The glutamate dehydrogenase structural gene of Escherichia coli. Mol Gen Genet 1990; 223: 508.
34. Delmonico FL, Conti D, Auchincloss H Jr, et al. Long-term, low-dose cyclosporine treatment of renal allograft recipients. A randomized trial. Transplantation 1990; 49: 899.
35. Sweny P, Lui SF, Scoble JE, Varghese Z, Fernando ON, Moorhead JF. Conversion of stable renal allografts at one year from cyclosporin A to azathioprine: a randomized controlled study. Transplant Int 1990; 3: 19.
36. Boer WH, Koomans HA, Dorhout Mees EJ. Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. Kidney Int 1987; 32: 376.
37. Carruthers SG, Freeman DJ, Koegler JC, Howson W, Keown PA, Laupacis A. Simplified liquid-chromatographic analysis for cyclosporin A and comparison with radioimmunoassay. Clin Chem 1983; 29: 180.
38. Redgrave TG, Roberts DCK, West E. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem 1975; 65: 42.
39. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 1: 467.
40. Pekelharing HL, Kleinveld HA, Duif PF, Bouma BN, van Rijn HJ. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 1996; 75: 497.
41. Dullaart RP, Gansevoort RT, Dikkeschei BD, de Zeeuw D, de Jong PE, Van Tol A. Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 1993; 44: 91.
42. Heyrowski A. A new method for determination of inulin in plasma and urine. Clin Chim Acta 1956; 1: 470.
43. Waugh WH, Beall PT. Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 1974; 5: 429.
44. Hueso M, Bover J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727.
45. Smak Gregoor PJ, Gelder van T, Kuiper de P, et al. Conversion of maintenance treatment with cyclosporine and prednisone to azathioprine or mycophenolate mofetil with prednisone one year after kidney transplantation (Abstract). Kidney Int 1999; 55: 2600.
46. Zanker B, Schneeberger H, Hillebrand G, et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression. Transplantation 1998; 66: 44.
47. Ducloux D, Fournier V, Bresson Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. Transplantation 1998; 65: 1504.
48. Rocher LL, Milford EL, Kirkman RL, Carpenter CB, Strom TB, Tilney NL. Conversion from cyclosporine to azathioprine in renal allograft recipients. Transplantation 1984; 38: 669.
49. Morris PJ, Chapman JR, Allen RD, et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987; 1: 586.
50. Kasiske BL, Heim Duthoy K, Ma JZ. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 1993; 269: 395.
51. Hilbrands LB, Hoitsma AJ, Koene KA. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61: 1038.
52. Kon V, Sugiura M, Inagami T, Harvie Br, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487.
53. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991; 88: 310.
54. Bloom ITM, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 1993; 114: 480.
55. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287.
56. Laine J, Holmberg C. Tubular effects of cyclosporine in pediatric renal transplant recipients. Transplant Proc 1996; 28: 2104.
57. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis 1996; 27: 701.
58. Zurcher RM, Bock HA, Thiel G. Hyperuricaemia in cyclosporin-treated patients: GFR-related effect. Nephrol Dial Transplant 1996; 11: 153.
59. Marcen R, Gallego N, Orofino L, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995; 70: 307.
60. Scoble JE, Freestone A, Varghese Z, Fernando ON, Sweny P, Moorhead JF. Cyclosporin-induced renal magnesium leak in renal transplant patients. Nephrol Dial Transplant 1990; 5: 812.
61. Schrama YC, Hené RJ, de Jonge N, et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients; an exercise provocation test. Transplantation 1998; 66: 1175.
62. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53.
63. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81: 26B.
64. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998; 81: 13B.
65. Sutherland WH, Restieaux NJ, Nye ER, et al. IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy. Arterioscler Thromb Vasc Biol 1998; 18: 577.
66. Hodis HN, Mack WJ, Dunn M, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022.
67. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28: 304.
68. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992; 152: 28.
69. Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 1993; 25: 431.
70. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737.
71. Ligtenberg JJM, Van Tol A, van Haeften TW, Sluiter JW, Reitsma WD, Dullaart RPF. Impaired suppression of plasma free fatty acids and triglycerides by acute hyperglycaemia-induced hyperinsulinaemia and alterations in high density lipoproteins in essential hypertension. J Intern Med 1996; 240: 233.
72. Atger V, Leclerc T, Cambillau M, et al. Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity. Atherosclerosis 1993; 103: 29.
73. Eberhard OK, Kliem V, Brunkhorst R. Five cases of kaposi's sarcoma in kidney graft recipients. Transplantation 1999; 67: 180.
74. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997: 64: 669.